Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Vasiliki Leventaki MD
Assistant Professor
Department of Pathology
Division of Administration

OFFICE ADDRESS:
Children's Hospital
9000 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:
10/1998 - 12/2004 MD, National and Kapodistrian University of Athens, Athens, Greece

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
03/2005 - 04/2007 Postdoctoral Research Fellow, Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX
07/2007 - 06/2011 Resident, Anatomical and Clinical Pathology, Department of Pathology, University of Utah, Salt Lake City, UT
07/2011 - 06/2013 Clinical Fellow, Hematopathology, Department of Hematopathology
The University of Texas, MD Anderson Cancer Center, Houston, Texas

FACULTY APPOINTMENTS:
2013 - 2015 Research Associate, Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
2015 - 2018 Assistant Member, Department of Pathology, St. Jude Children's Research, Memphis, TN
2018 - Present Assistant Professor, Department of Pathology, Medical College of Wisconsin, Milwaukee, WI

HOSPITAL STAFF PRIVILEGES:
01/2019 - Present Children's Hospital of Wisconsin, Milwaukee, WI
01/2019 - Present Froedtert Memorial Lutheran Hospital, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
American Board of Pathology, Anatomic and Clinical Pathology
07/2011
12/2021
American Board of Pathology, Hematology/Pathology
09/2012
12/2022
 
Licensure
Number Issue DateExpiration
State of Utah
7159567-1205
10/20/2008
01/31/2020
State of Tennessee
50144
06/18/2013
02/28/2020
State of Wisconsin
70319
11/28/2018
10/31/2019
 

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
2005 - Present American Society of Hematology
2007 - Present College of American Pathologists
2013 - Present Children's Oncology Group
2013 - Present American Society for Clinical Pathology

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Prior
Non-Peer Review
Title:
Resident Research Grant
Source:
College of American Pathologists
Role:
Mentor: Robert M. Miles
Dates:
2010 - 2011
Direct Funds:
$2,500
 

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
National
Vasiliki Leventaki, Uncommon Leukemic Presentation of Anaplastic Large Cell Lymphoma. Hematopathology Evening Specialty Conference, USCAP, March 17, 2019, National Harbor, Maryland
Vasiliki Leventaki, Lymphoid neoplasms: 2008 WHO classification and current updates. Invited lecture at the American Medical Technologist (AMT) 78th National Meeting 2016, Memphis, TN
 
International
Vasiliki Leventaki, Pediatric Leukemia, Pediatric Pathology CME, TATA Medical Center, Kolkata, 01/18/2019 - 01/20/2019
Vasiliki Leventaki, Pediatric Lymphoma, Pediatric Pathology CME, TATA Medical Center, Kolkata, 01/18/2019 - 01/20/2019
Vasiliki Leventaki, Histiocytic Proliferations, Asociacion de Hemato-Oncologia Pediatrica de Centro America (AHOPCA), February 18-20, Costa Rica, Panama 2019
Vasiliki Leventaki. Pediatric Lymphomas, Asociacion de Hemato-Oncologia Pediatrica de Centro America (AHOPCA), February 21-23, Panama 2018
 

MEDICAL COLLEGE TEACHING ACTIVITIES:
Resident and Fellow Education
01/2019 - Present Hematopathology Rotation at Froedtert Memorial Lutheran Hospital, Pathology Residents
01/2019 - Present Hematopathology Rotation at Children's Hospital of Wisconsin, Pediatric Hematology/Oncology Fellows
 


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Graetz D, Crews KR, Azzato EM, Singh RK, Raimondi S, Mason J, Valentine M, Mullighan CG, Holland A, Inaba H, Leventaki V. Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib. Haematologica. 2019 May;104(5):e218-e221
2. Bjornard KL, Leventaki V, Nichols KE, Sandlund JT, Prockop S, Ehrhardt MJ. Two year-old female with EBV-positive diffuse large B-cell lymphoma and subsequent CNS involvement with neurolymphomatosis. Pediatr Blood Cancer. 2018 Dec;65(12):e27415
3. Leventaki V, Flerlage J. Sarcoid-like granulomatosis in a patient receiving anti-TNFα For psoriasis. Am J Hematol. 2 2018 May;93(5):722-72
4. Wei EX, Leventaki V, Choi JK, Raimondi SC, Azzato EM, Shurtleff SA, Ong MG,Leventaki V, Veillon DM, Cotelingam JD, Shackelford RE. γδ T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Discussion of Two Pediatric Cases and Its Distinction from Other Mature γδ T-Cell Malignancies. Case Rep Hematol. 2017:5873015
5. Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros LJ, Young KH, Rassidakis GZ. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017 Jul;31(7):1633-1637
6. Palacios G, Shaw T, Li Y, Singh RK, Valentine M, Sandlund JT, Lim MS, Mullighan CG, Leventaki V. Novel ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1 complex. Leukemia. 2017 Mar; 31(3):743-747
7. Helton KJ, Maron G, Mamcarz E, Leventaki V, Patay Z, Sadighi Z. Unusual magnetic resonance imaging presentation of post-BMT cerebral toxoplasmosis masquerading as meningoencephalitis and ventriculitis. Bone Marrow Transplant. 2016 Nov;51(11):1533-1536
8. Ferguson-Paul K, Mangum S, Porter A, Leventaki V, Campbell P, Wolf J. Hemophagocytic Lymphohistiocytosis and Progressive Disseminated Histoplasmosis. Emerg Infect Dis. 2016 Jun;22(6):1119-21
9. Ok CY, Leventaki V, Wang SA, Dinardo C, Medeiros LJ, Konoplev S. Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy. Am J Clin Pathol. 2016 Feb;145(2):271-6
10. Pan Y, Wang S, Su B, Zhou F, Zhang R, Xu T, Zhang R, Leventaki V, Drakos E, Liu W, Claret FX. Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression. Oncogene. 2017 Feb 23;36(8):1069-107
11. Atsaves V, Zhang R, Ruder D, Pan Y, Leventaki V, Rassidakis GZ, Claret FX. Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism. Leukemia. 2015 Nov;29(11):2162-72
12. Atsaves V, Lekakis L, Drakos E, Leventaki V, Ghaderi M, Baltatzis GE, Chioureas D, Jones D, Feretzaki M, Liakou C, Panayiotidis P, Gorgoulis V, Patsouris E, Medeiros LJ, Claret FX, Rassidakis GZ. The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.Br J Haematol. 2014 Nov;167(4):514-23
13. Leventaki V, Drakos E, Karanikou M, Psatha K, Lin P, Schlette E, Eliopoulos A, Vassilakopoulos TP, Papadaki H, Patsouris E, Medeiros LJ, Rassidakis GZ. c-JUN Nterminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma. Hum Pathol. 2014 Mar;45(3):565-72
14. Leventaki V, Manning JT Jr, Luthra R, Mehta P, Oki Y, Romaguera JE, Medeiros LJ, Vega F. Indolent peripheral T-cell lymphoma involving the gastrointestinal tract. Hum Leventaki V. Pathol. 2014 Feb;45(2):421-6
15. Kunkalla K, Liu Y, Qu C, Leventaki V, Agarwal NK, Singh RR, Vega F. Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype. Ann Hematol. 2013 Jun;92(6):777-87
16. Leventaki V*, Rodic V, Tripp SR, Bayerl MG, Perkins SL, Barnette P, Schiffman JD, Miles RR. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases. Br J Haematol 2012 158(6):763-771. *This work was partially supported by a Resident Research Grant from the College of American Pathologists Foundation.
17. Kim Y, Leventaki V, Bhaijee F, Jackson CC, Medeiros LJ, Vega F. Extracavitary/solid variant of primary effusion lymphoma. Ann Diagn Pathol. 2012 Dec;16(6):441-6
18. Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, Kantarjian H, Huh Y, Ravandi F. Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymph 2012 53(9):1839-1841
19. Liakou P, Tepetes K, Germenis A, Leventaki V, Atsaves V, Patsouris E, Roidis N, Hatzitheophilou K, Rassidakis GZ. Expression patterns of endothelin-1 and its receptors in colorectal cancer. J Surg Oncol. 2012 Jun 1;105(7):643-9
20. Drakos E, Leventaki V, Atsaves V, Schlette EJ, Lin P, Vega F, Miranda RN, Claret FX, Medeiros LJ, Rassidakis GZ. Expression of serine 194-phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell non-Hodgkin lymphomas. Hum Pathol 2011 42(8):1117-1124
21. Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, Parker-Thornburg J, Shackleford TJ, Dai H, Lin SY, Lozano G, Rassidakis GZ, Claret FX. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene 2010 29(46):6125-6137
22. Chen W, Drakos E, Grammatikakis I, Schlette EJ, Li J, Leventaki V, Staikou-Drakopoulou E, Patsouris E, Panayiotidis P, Medeiros LJ, Rassidakis GZ. mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Mol Cancer. 2010 Nov 10; 9:292
23. Inamdar KV, Romaguera JE, Drakos E, Knoblock RJ, Garcia M, Leventaki V, Medeiros LJ, Rassidakis GZ. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine. Cancer 2009 115(20):4727-4736
24. Chen W, Konoplev S, Medeiros LJ, Koeppen H, Leventaki V, Vadhan-Raj S, Jones D, Kantarjian HM, Falini B, Bueso-Ramos CE. Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. Cancer 2009 115(23):5481-5489
25. Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, Medeiros LJ, Rassidakis GZ. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia 2009 23(4):784-790
26. Cotta CV, Leventaki V, Atsaves V, Vidaki A, Schlette E, Jones D, Medeiros LJ, Rassidakis GZ. The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas. Leukemia. 2009 Apr;23(4):784-90
27. Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff M, Rassidakis GZ. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res 2007 13(11):3380-3387
28. Drakos E, Rassidakis GZ, Leventaki V, Guo W, Medeiros LJ, Nagarajan L. Differential expression of the human MIXL1 gene product in non-Hodgkin and Hodgkin lymphomas. Hum Path 2007 38(3):500-7
29. Leventaki V, Drakos E, Lim SM, Elenitoba-Johnson SK, Claret FX, Medeiros LJ, Rassidakis GZ. NPM-ALK oncogenic kinase promotes cell cycle progression through activation of JNK/cJun in anaplastic large cell lymphoma. Blood 2007 110(5):1621-1630
30. Drakos E, Leventaki V, Schlette EJ, Jones D, Lin P, Medeiros LJ, Rassidakis GZ. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders. Am J Surg Pathol 2006 31(3):447-453
31. Peponi E*, Drakos E*, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ (*equal contribution). Activation of mTOR signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 2006 169(6):2171-2180
32. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret F-X, Rassidakis GZ. Activation of mTOR Signaling Pathway Contributes to Tumor Cell Survival in ALK+ anaplastic large cell lymphoma. Cancer Res 2006 66(13):6589-6597
33. Oyarzo MP, Medeiros LJ, Atwell C, Feretzaki M, Leventaki V, Wang S, Drakos E, Amin HM, Rassidakis GZ. c-FLIP Confers Resistance to Fas-mediated apoptosis in anaplastic large cell lymphoma. Blood 2006 107(6):2544-2537
34. Lai R, Leventaki V, Rassidakis GZ. Re: Rust et al. TIMP-1 expression in anaplastic large cell lymphoma is usually restricted to macrophages and only seldom observed in tumour cells. J Pathol 2005 206:445-450
35. Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, Leventaki V, Das P, Rassidakis GZ, Cutler C, Medeiros LJ, Lai R. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 2004 23(32):5426-5434
36. Amin H, Medeiros LJ, Ma Y, Feretzaki M, Das P, Leventaki V, Rassidakis GZ, O'Connor SL, McDonnell TJ, Lai R. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 2003 22(35):5399-5407
37. Lai R, Rassidakis GZ, Medeiros LJ, Leventaki V, Keating M, McDonnell TJ. Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumors. J Pathol 2003 199(1):84-89
38. Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V, Schmitt-Graeff A, Herling M, Amin HM, Lai R. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res 2003 9(10):3692-3699
39. Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O'Connor SL, Keating MJ, Lai R. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med 2003 127(4):424-431
 
Books, Chapters, and Reviews
1. Leventaki V, Vega F. Lymphoid Malignancies: Molecular Diagnostics. In: Molecular Genetic Pathology. p.887-928. Springer, 2013 (2nd Edition)
 
Abstracts
1. Shaw T, Pounds S, Cao X, Palacios G, Mason J, Perkins S, Kinney M, Kraveka J, Gross T, Sandlund JT, Mullighan CG, Lim MS, Leventaki V. "An integrated analysis of DNA methylation and transcriptome profiles identifies two distinct groups of pediatric ALK-positive anaplastic large cell lymphoma.107st United States and Canadian, Academy of Pathology Annual Meeting, March 17-23, 2018, Vancouver, BC, Canada
2. Palacios G, Shaw T, Li Y, Singh RK,Valentine M, Sandlund JT, Lim MS, Mullighan CG. Leventaki V. EEF1G is a New Partner of ALK in Anaplastic Large Cell LymphomaInducing constitutive ALK Tyrosine Kinase Activation.. 17th Society forHematopathology/European Association of Haematopathology Workshop, September 3-8, 2016, Basel, Switzerland
3. Leventaki V, Liu Y, Kunkalla K, Singh RR, Agarwal NK, and Vega F Aldehyde Dehydrogenase 1 (ALDH1) is a Novel Marker for Tumor-associated Macrophages and Dendritic Cells in Mature B-cell Lymphomas. 102st United States and Canadian Academy of Pathology Annual Meeting, March 2-8, 2013, Baltimore, MD
4. Leventaki V, Sargent RL, Vega F. Intravascular T-cell lymphoma with cytotoxic T-cell phenotype. 16th Society for Hematopathology/European Association of Haematopathology Workshop, October 20-25, 2012, Lisbon, Portugal
5. Leventaki V, Bourbon E, Qu C, Liu Y, MD, Kunkalla K, Nyguyen M, Bueso-Ramos C, Singh RR, Agarwal NK, and Vega F. Diffuse Large B-Cell Lymphoma Cells Promotes Paracrine Activation of NF-kB Pathway in Tumor-Associated Stromal Cells. 101st United States and Canadian Academy of Pathology Annual Meeting, March 17-23, 2012, Vancouver, BC, Canada
6. Leventaki V, Rodic V, Jahromi MS, Downie JM, Tripp SR, Bayerl MG, Perkins SL, Barnette P, Schiffman JD, Miles RR. Characterization of the p53-Human homolog of the Murine Double Minute 4 (HDM4) pathway in Pediatric Burkitt Lymphoma and Correlation with Copy Number Alterations. 100th United States and Canadian Academy of Pathology Annual Meeting, Feb 26-March 4, 2011, San Antonio, TX
7. Leventaki V, Drakos E, Claret F-X, Medeiros LJ, Rassidakis GZ. cJun is Phosphorylated at Ser73 and Contributes to Cell Cycle Progression in Anaplastic Large Cell Lymphoma. American Society of Hematology, 47th Annual Meeting, December 10-13, 2005, Atlanta, GA
 

jenkins-FCD Prod-410 e9586552fe7f53c71f7923aa6e27aeabbd3c2473